2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...
Medical Dialogues15 小时
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million
Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
一夜暴涨76%！蓝鸟生物分拆公司“嫁入”百时美施贵宝
2seventy bio是蓝鸟生物（bluebird bio）战略分拆的产物。2021年初，蓝鸟生物做出了一个具有深远影响的战略决策。为了在基因疗法和细胞疗法这两个业务单元实现更高效、快速的科学突破，公司决定进行拆分。
美股内部交易 | 2seventy bio于3月13日披露3笔公司内部人交易情况
2025年3月13日， 2seventy bio（TSVT）披露3笔公司内部人交易情况。持股10%以上股东Kynam Global Healthcare Master Fund, LP于2025年3月11日卖出595.38万股。 2025年3月13日 持股10%以上股东 Kynam Global Healthcare Master Fund, LP 2025年3月11日 卖出 1623.80万 4 ...
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
2seventy bio暴涨76% 百时美施贵宝将以约2.86亿美元收购该公司
细胞疗法公司2seventy bio (TSVT.US)暴涨76%，报4.93美元。消息面上，百时美施贵宝将以约2.86亿美元的现金收购2seventy bio。每股5美元的收购价格较该股上周五的收盘价溢价88%。两家公司已合作开发一种CAR T细胞疗法Abecma，用于治疗一种名为多发性骨髓瘤的血癌。 (格隆汇) ...
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...
2seventy bio (TSVT) was downgraded to a Hold Rating at Leerink Partners
In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...
Fintel on MSN3 天
Leerink Partners Downgrades 2seventy bio (TSVT)
Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...
GEN - Genetic Engineering and Biotechnology News3 天
BMS to Acquire Abecma Partner 2seventy bio for $286M
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.